Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory
cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet …

Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …

The natural history of cancers can be understood through the lens of evolution given that the
driving forces of cancer development are mutation and selection of fitter clones. Cancer …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer entity characterized by a
heterogeneous genetic landscape and an immunosuppressive tumor microenvironment …

Recent studies have emphasized the importance of single-cell spatial biology, yet available
assays for spatial transcriptomics have limited gene recovery or low spatial resolution. Here …

Pancreatic ductal adenocarcinomas are distinguished by their robust desmoplasia, or
fibroinflammatory response. Dominated by non-malignant cells, the mutated epithelium must …

Immunotherapies have shown benefits across a range of human cancers, but not pancreatic
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …

Cancers display significant heterogeneity with respect to tissue of origin, driver mutations,
and other features of the surrounding tissue. It is likely that individual tumors engage …